Novo Nordisk shares up on positive weight loss drug trial
Pharmaceutical giant Novo Nordisk were up double digits early on Friday thanks to positive headline results from early-stage trials into one of its weight loss drugs.
Novo Nordisk A S
24 January 2025 14:11:28
Source: Sharecast
Novo Nordisk said the trial showed that its once-weekly amycretin obesity drug resulted in an average weight reduction of 22% in obese and overweight patients after 36 weeks, compared to a weight gain of 2.0% among patients treated with placebo.
"We are very encouraged by the subcutaneous phase 1b/2a results for amycretin in people living with overweight or obesity,” said executive vice president for development Martin Lange.
"The results seen in the trial support the weight lowering potential of this novel unimolecular GLP-1 and amylin receptor agonist, amycretin, that we have previously seen with the oral formulation."
As of 1410 GMT, Novo Nordisk shares were up 12.12% in pre-market trading at $90.93 each.
Reporting by Iain Gilbert at Sharecast.com
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Bank of Scotland is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
Important legal information
Bank of Scotland Share Dealing Service is operated by Halifax Share Dealing Limited. Halifax Share Dealing Limited. Registered in England and Wales No. 3195646. Registered Office: Trinity Road, Halifax, West Yorkshire HX1 2RG. Authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.
The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.
